Zeven (dalbavancin) / RaQualia, AbbVie - LARVOL DELTA

Antimicrobial Management Strategies for Multidrug-Resistant Gram-positive Prosthetic Device Infections. (PubMed, Infect Dis Clin North Am) - "This review examines management strategies for methicillin-resistant staphylococci, ampicillin-resistant enterococci, vancomycin-resistant enterococci, and MDR Corynebacterium infections. Vancomycin remains the cornerstone for most resistant organisms, while newer agents like dalbavancin enable outpatient therapy. Critical considerations include recognizing linezolid toxicity during prolonged therapy, and understanding that surgical approach determines outcomes more than antimicrobial selection."

Journal • Review • Infectious Disease

Predicting prolonged dalbavancin exposure using machine learning: a validated strategy for individualized redosing. (PubMed, Antimicrob Agents Chemother) - "This ML-based approach enables early individualized redosing decisions using minimal clinical inputs. By complementing Bayesian forecasting and reducing reliance on serial sampling, it represents a pragmatic strategy to support model-informed precision dosing of dalbavancin."

Journal • Infectious Disease

Identification of the orange pigment in Nonomuraea gerenzanensis and development of a pigment-free mutant with high yield of A40926. (PubMed, AMB Express) - "The secondary metabolite A40926, a precursor to the glycopeptide antibiotic dalbavancin, is synthesized by the rare actinomycete Nonomuraea gerenzanensis (N...Consequently, the overexpression of the global regulator Crp significantly enhanced A40926 production, achieving a yield of 841.1 mg/L. The investigation of pigment-free mutants presented in this study offers valuable insights for effectively reducing production costs within the microbial pharmaceutical industry."

Journal

Relationship Between Patient's Body Mass Index and Dalbavancin's Effectiveness in the Treatment of Invasive Gram-Positive Infections. (PubMed, Ann Pharmacother) - "This observational study did not show an association between BMI and TF in patients treated with dalbavancin with invasive gram-positive infections."

Journal • Genetic Disorders • Infectious Disease • Obesity

Recent advances in the management of skin and soft tissue infections. (PubMed, Curr Opin Infect Dis) - "Even if SSTIs remain a difficult condition to treat, causing significant morbidity, mortality and economic burden on healthcare systems, ongoing scientific research is attempting to improve both diagnostic methods and treatment. More developments are expected in the near future in the areas of innovative diagnostic techniques, innovative drugs, nanotechnology applications, and antigen-based therapies."

Journal • Infectious Disease

Long-Term Therapy with Long-Acting Lipoglycopeptide Antibiotics in the Treatment of Cardiovascular Prosthetic Infections: A Systematic Review. (PubMed, Antibiotics (Basel)) - "Background: Dalbavancin and oritavancin are long-acting lipoglycopeptides increasingly used off-label for a variety of Gram-positive infections. This systematic review was registered on Open Science Framework. This work was supported by grants from the Italian Ministry of Health through Ricerca Corrente, Linea 3, Progetto 3."

Journal • Review • Cardiovascular • Infectious Disease • Inflammation

Dalbavancin for Bone and Joint Infections: A Two-Center Greek Real-World Retrospective Study. (PubMed, Pathogens) - "Dalbavancin was administered as monotherapy (32.4%) or combined with other antibiotics (67.6%), mainly fluoroquinolones (63.6%) and minocycline (23.6%). Dalbavancin demonstrated high efficacy, favourable safety, and treatment simplification in complex bone and joint infections. Its long half-life and reduced need for prolonged IV access support its role in minimizing hospitalization and catheter-related complications, particularly in regions with limited outpatient parenteral therapy infrastructure."

Journal • Real-world evidence • Retrospective data • Acute Kidney Injury • Cardiovascular • Coronary Artery Disease • Diabetes • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Nephrology • Renal Disease • Rheumatology

Dalbavancin as Suppressive Therapy for Implant-Associated Osteoarticular Infections. (PubMed, Antibiotics (Basel)) - " Dalbavancin is shown to be a safe and convenient alternative for SAT for orthopaedic implant infection. Although the development of resistance was infrequent, it can occur and should be monitored."

Journal • Infectious Disease • Orthopedics

How to use novel antimicrobials beyond official indications: an expert consensus. (PubMed, JAC Antimicrob Resist) - "The process comprised three survey rounds evaluating off-label uses of eight drugs: ceftazidime-avibactam, ceftolozane-tazobactam, cefiderocol, ceftaroline, ceftobiprole, dalbavancin, tedizolid, and isavuconazole. The guidance prioritizes targeted treatment over empirical use, aligning with international ASP principles and WHO recommendations. These results provide a regional reference to optimize ASP initiatives focus on new antibiotic use while minimizing ecological impact and resistance development."

Journal • Cardiovascular • Critical care • Infectious Disease

Difficult-to-Treat Skin and Soft Tissue Infections Caused by Panton-Valentine Leukocidin-Producing Community-Associated Methicillin-Resistant Staphylococcus aureus: A Case Series. (PubMed, Infect Dis Rep) - "Long-acting lipoglycopeptides (oritavancin or dalbavancin) were evaluated as therapeutic options to achieve clinical resolution. PVL-positive CA-MRSA infections are characterized by recurrence, intrafamilial clustering, and frequent therapeutic failure with standard oral agents. Effective management requires an integrated approach combining prompt surgical drainage; systemic therapy, preferably including long-acting lipoglycopeptides; and comprehensive decolonization of all close contacts."

Journal • Infectious Disease

Novel lytic phages improve the antibiofilm activity of dalbavancin, daptomycin, and fosfomycin against vancomycin-resistant enterococci. (PubMed, Microbiol Spectr) - "These findings provide proof of concept that combining phages with antibiotics enhances efficacy against multidrug-resistant Enterococcus biofilms, offering a translational pathway for personalized, adjunctive therapies in complex orthopedic infections. By bridging the gap between genomic phage safety validation and functional synergy testing, this work supports further preclinical and clinical development of phage-antibiotic strategies for refractory implant-associated infections."

Journal • Infectious Disease • Orthopedics

Oritavancin for Treatment of Osteomyelitis: A Systematic Review and Meta-Analysis of Observational Studies. (PubMed, Pharmacotherapy) - "Despite previous warnings, we found no evidence of ineffectiveness with ORI for OM. ORI's infrequent dosing schedule may provide convenience over daily parenteral therapy, particularly for difficult-to-treat pathogens like MRSA and VRE. Further research is needed to optimize dosing strategies based on pathogen susceptibility and establish appropriate therapeutic drug monitoring protocols."

Journal • Observational data • Retrospective data • Infectious Disease • Inflammation • Musculoskeletal Diseases • Orthopedics

Therapeutic options and prognostic risk factors in diabetic foot osteomyelitis: a narrative review. (PubMed, Int J Surg) - "Emerging antimicrobial agents such as dalbavancin, tedizolid, and novel cephalosporins, alongside bacteriophage therapy and immunomodulatory strategies like granulocyte colony-stimulating factor (G-CSF), show promise in improving infection management. Prognosis heavily depends on glycemic control, renal function, immune status, and cardiovascular health. Comprehensive multidisciplinary management is crucial to improving patient outcomes, reducing amputations, and enhancing quality of life."

Journal • Cardiovascular • Diabetes • Infectious Disease • Inflammation • Musculoskeletal Diseases • Orthopedics

An Uncommon Reaction: Dalbavancin Induced DRESS Without Eosinophilia (ACAAI 2025) - "Initially treated with vancomycin, he developed flushing and pruritus and was therefore transitioned to dalbavancin...A systemic prednisone taper resulted in clinical improvement...This case highlights the importance of clinical vigilance when using dalbavancin, particularly in patients who have been previously sensitized to glycopeptides. Early identification and treatment with systemic corticosteroids are essential for favorable outcomes, and further pharmacovigilance is warranted as long-acting antibiotics become more widely used."

Dermatology • Eosinophilia • Immunology • Infectious Disease • Inflammation • Pruritus

Acute Hepatitis During Dalbavancin Infusion: A Rare Adverse Reaction With Implications for Repeat Dosing (ACG 2025) - "He subsequently completed therapy with cefazolin and linezolid and was placed on oral cefadroxil plus doxycycline suppression in view of retained hardware. In pooled data from 2,120 adults across phase 1–3 studies, 17 patients (0.8%) developed post-baseline ALT elevations >3× ULN; within this group, 5 (0.2%) had ALT >10× ULN and one phase 1 subject exhibited ALT >20× ULN—each reversible on follow-up (Table 2)...In this case likely mechanisms include immune-mediated hypersensitivity, similar to vancomycin-induced hepatotoxicity, although rate of cross-reactivity between dalbavancin and vancomycin appears to be very low to negligible...Laboratory Values Pre-infusion and Post-infusion of Dalbavancin Figure: Table 2. ALT Elevation Secondary to Dalbavancin Infusion Regiments"

Fatigue • Hepatology • Immunology • Infectious Disease • Inflammation

Real-world effectiveness of dalbavancin for invasive gram-positive bacterial infections. (PubMed, Am J Health Syst Pharm) - "Dalbavancin is a safe and effective treatment option for invasive GPIs; however, risk factors are associated with higher odds of clinical failure."

Journal • Real-world evidence • Infectious Disease • Inflammation

Diphtheria-like Pseudomembranous Corynebacterium striatum Chronic Infection of Left Ventricular Assist Device Driveline Bridged to Heart Transplantation with Dalbavancin Treatment. (PubMed, Reports (MDPI)) - "The patient experienced recurrent episodes of C. striatum bacteremia despite multiple courses of targeted antibiotic therapy, including vancomycin, linezolid, tedizolid, teicoplanin, and dalbavancin. Histopathological analysis revealed necrotic elements and Gram-positive organisms consistent with pseudomembranous inflammation. The case describes the diagnosis and treatment of this rare infection, highlighting the pathogenic potential of C. striatum, its role in device-related infections, and the histopathological evidence of pseudomembrane formation."

Journal • Cardiovascular • Infectious Disease • Inflammation • Transplantation

Efficacy, safety, and population pharmacokinetics of a single 1500mg dose of dalbavancin for short-term therapy in patients with chronic prosthetic joint infections. (PubMed, Antimicrob Agents Chemother) - "After 11.5 days of intravenous antibiotic therapy (vancomycin, 75%), patients received 1,500 mg of dalbavancin without adverse events. A single 1,500 mg dose of dalbavancin combined with antibiotic-loaded spacers may be an effective and safe sequencing treatment for CPJI and provide 3-4 weeks of therapeutic exposure for susceptible microorganisms. Considering dalbavancin's unique pharmacokinetics, this approach may be considered in the clinical management of CPJI."

Journal • PK/PD data • Infectious Disease

Real-World Use of Dalbavancin in Diabetic Foot Osteomyelitis: PEDDAL Study. (PubMed, J Clin Med) - "Chronic kidney disease was the sole independent risk factor for therapeutic failure (IRR 0.80, 95% CI: 0.64-1.00, p = 0.045). Dalbavancin is effective and safe for treating diabetic foot osteomyelitis, including in complex patients with resistant microorganisms."

Clinical • Journal • Real-world evidence • Chronic Kidney Disease • Infectious Disease • Inflammation • Nephrology • Renal Disease

Budget Impact and Financial Analysis of Outpatient Dalbavancin in an Urban, Non-Teaching, Community Hospital. (PubMed, Clin Drug Investig) - "Outpatient dalbavancin utilization presents an opportunity to realize net positive reimbursement and minimize pharmacy drug acquisition costs. Our study suggests that dalbavancin utilization presents significant cost advantages over intravenous daptomycin in both short and long treatment durations and over oral linezolid in long durations."

HEOR • Journal • Immunology • Infectious Disease • Inflammation • Rheumatology

In vitro and in vivo efficacy of vancomycin against Elizabethkingia species and the impact of increased vancomycin MICs. (PubMed, Microbiol Spectr) - "Vancomycin improved Galleria mellonella survival in a dose-dependent manner, whereas teicoplanin, dalbavancin, oritavancin, and daptomycin were ineffective...Most commonly considered agents, including fluoroquinolones, piperacillin/tazobactam, and trimethoprim/sulfamethoxazole, are increasingly compromised by resistance, toxicity, or inconsistent efficacy...These findings suggest vancomycin may offer therapeutic benefit when no preferred options are available. They support cautious use in selected cases and highlight the need for continued monitoring of susceptibility and resistance development."

Journal • Preclinical • Infectious Disease

Dalbavancin to Complete a Prolonged Antibiotic Course for Persistent Bacillus cereus Bacteremia: A Case Report and Literature Review. (PubMed, Case Rep Infect Dis) - "Gentamicin was initiated for Gram-positive synergistic effect with vancomycin. On discharge, he received one dose of dalbavancin and oral levofloxacin for 21 days to complete a total 4-week antibiotic course from date of blood culture clearance. This case demonstrates that dalbavancin may be a promising alternative to standard treatments for prolonged antibiotic courses of B. cereus infections, particularly when intravenous access is a challenge."

Journal • Gastroenterology • Gastrointestinal Disorder • Infectious Disease

Dalbavancin dosing in a severely underweight woman with prosthetic valve endocarditis: the critical role of proactive therapeutic drug monitoring. (PubMed, J Antimicrob Chemother) - No abstract available

Journal • Cardiovascular

[Translated article] Therapeutic drug monitoring of dalbavancin: A systematic review of strategies and clinical applications in the treatment of complex infections. (PubMed, Farm Hosp) - "The use of Therapeutic Drug Monitoring in dalbavancin dosing optimizes the treatment of complex chronic infections by adjusting dosing intervals and maintaining adequate therapeutic levels over extended periods. However, further validation and definition of specific pharmacokinetic/pharmacodynamic targets is required."

Journal • Review • Infectious Disease

From Hidradenitis Suppurativa to PsAPASH Syndrome: The Role of Targeted Antibiotic Therapy in a Complex Case (EADV 2025) - "Following a suboptimal response to adalimumab, wound swabs identified Corynebacterium amycolatum. The patient was treated with linezolid followed by dalbavancin, in addition to ongoing biologic therapy, with partial clinical improvement... This case highlights the potential utility of microbiological assessment in patients with PsAPASH syndrome and non-healing PG or HS lesions, particularly in cases where standard therapies fail to achieve adequate clinical improvement. Although antibiotics are not considered a first-line treatment, their use may provide adjunctive benefit in selected scenarios, especially when guided by culture data. Further studies are needed to clarify the clinical significance of biofilm in PsAPASH syndrome."

Clinical • Acne Vulgaris • Crohn's disease • Dermatology • Gastroenterology • Hepatology • Hidradenitis Suppurativa • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Psoriasis • Psoriatic Arthritis • Pyoderma Gangrenosum • Rheumatology • Seronegative Spondyloarthropathies